Continuous subcutaneous insulin infusion in neonatal diabetes mellitus

Wintergerst, Kupper A.; Hargadon, S.; Hsiang, Helen Y.

doi:10.1111/j.1399-543x.2004.00067.x

Cited by 25 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bharucha et al 13 described two infants who attained euglycemia once transitioned to CSII after failing to maintain glycemic control by subcutaneous insulin injections. Wintergerst et al 21 described a premature baby boy with severe growth retardation who developed diabetes on Day 2 of life. In this case, glycemic control had been also affected by medical complications, such as necrotizing enterocolitis, poor weight gain, and cholestatic jaundice.…”

Section: Treatment Of Neonatal Diabetes Mellitusmentioning

confidence: 99%

Treatment of Transient Neonatal Diabetes Mellitus: Insulin Pump or Insulin Glargine? Our Experience

Passanisi

TimpanaroTiziana

PrestiDonatella

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Neonatal diabetes mellitus (NDM) results from impaired insulin secretion, occurring within the first 6 months of life. NDM is classified as transient NDM (TNDM) or permanent NDM. To date there are no universal guidelines regarding its management. Intravenous insulin infusion represents the first and most adequate therapeutic approach for sustained hyperglycemia, but this can provide only a short-term solution. Several factors should be taken into account in the choice of the long-term treatment. We describe our experience with two infants affected by TNDM. The first child was treated with continuous subcutaneous insulin infusion, whereas the second infant was treated with subcutaneous insulin glargine injections. Our experience shows that the two different therapeutic approaches, if properly managed, are equally effective.

show abstract

Section: Treatment Of Neonatal Diabetes Mellitusmentioning

confidence: 99%

Treatment of Transient Neonatal Diabetes Mellitus: Insulin Pump or Insulin Glargine? Our Experience

Passanisi

TimpanaroTiziana

PrestiDonatella

et al. 2014

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…It is also considered a safe and well-accepted method for pediatric diabetes14,15). Some researchers have described the safety and efficacy of CSII in NDM4,5,16). However, there is no consensus on the use of insulin pump for NDM, and it is not widely used in clinical practice for treatment of NDM.…”

Section: Discussionmentioning

confidence: 99%

“…There are several reports on insulin pump therapy for NDM, but there is no consensus on the use of insulin pump therapy for NDM4,5). We present our recent experience with insulin pump therapy in TNDM, in which stable glycemic control was achieved without any complications.…”

Section: Introductionmentioning

confidence: 95%

Insulin pump therapy in transient neonatal diabetes mellitus

Park

Kang

Lee

et al. 2013

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Neonatal diabetes mellitus (NDM) is a rare disease requiring insulin treatment. Its treatment is primarily focused on maintaining adequate glycemic control and avoiding hypoglycemia. Although insulin pump therapy is frequently administered to adults and children, there is no consensus on the use of insulin pumps in NDM. A 10 day-old female infant was referred to us with intrauterine growth retardation and poor weight gain. Hyperglycemia was noted, and continuous intravenous insulin infusion was initiated. However, the patient's serum glucose levels fluctuated widely, and maintaining the intravenous route became difficult within the following weeks. Continuous subcutaneous insulin infusion with an insulin pump was introduced on the twenty-fifth day of life, and good glycemic control was achieved without any notable adverse effects including hypoglycemia. We suggest that the insulin pump is a safe and effective mode for treating NDM and its early adoption may shorten the length of hospital stays in patients with NDM.

show abstract

“…Ähnliche Ergebnisse finden sich auch bei anderen Arbeitsgruppen [17,24]. Auch bei Säuglingen mit allen Formen des neo natalen Diabetes mit substitutionsbedürf tigem Insulinbedarf wird die CSII als The rapie grundsätzlich empfohlen [6,25].…”

Section: Senkung Der Hypoglykämierateunclassified

Insulinpumpentherapie in der Pädiatrie

et al. 2007

View full text Add to dashboard Cite

Die Insulinpumpentherapie oder CSII ("continuous subcutaneous insulin infusion") wird in den letzten 10-15 Jahren zunehmend in der Therapie bei Kindern und Jugendlichen mit Diabetes mellitus eingesetzt. Sie stellt in der Behandlung pädia-trischer Patienten keine Ausnahme mehr dar, vielmehr ist sie neben der Spritzentherapie, ob CT ("conventional therapy", konventionelle Therapie) oder ICT (intensivierte konventionelle Therapie) fest etabliert. Dennoch sind in Bezug auf Indikationen, Voraussetzungen, Schulung und ambulante Betreuung wichtige Aspekte zu beachten.

show abstract

Continuous subcutaneous insulin infusion in neonatal diabetes mellitus

Cited by 25 publications

References 24 publications

Treatment of Transient Neonatal Diabetes Mellitus: Insulin Pump or Insulin Glargine? Our Experience

Treatment of Transient Neonatal Diabetes Mellitus: Insulin Pump or Insulin Glargine? Our Experience

Insulin pump therapy in transient neonatal diabetes mellitus

Insulinpumpentherapie in der Pädiatrie

Contact Info

Product

Resources

About